IGA, EASI, and Itch Endpoints Met in First In Human Phase 2 Trial of Zabalafin for Atopic Dermatitis
Dermatology Times
FEBRUARY 9, 2024
Interim data from the clinical trial was presented in a poster at the South Beach Symposium, with itch reduction demonstrating immediacy and long-term capability.
Let's personalize your content